Skip to main content
. 2013 Jan 8;21(4):887–894. doi: 10.1038/mt.2012.265

Figure 5.

Figure 5

Coadministration of VSV and MS-275 depleted Treg numbers leaving residual Tregs with lower FoxP3 expression levels. Ad-hDCT-primed C57BL/6 mice were boosted with VSV-hDCT in the presence of MS-275, MS-275 analogue or carrier as detailed in Figure 2. (a) The kinetics of CD4+/FoxP3+ Tregs in blood following treatment. (b) The level of Treg expression of FoxP3 as measured by mean fluorescence intensity on day 7 after treatment. (c) The ratio of DCT-specific CD8+ T cells to CD4+/FoxP3+ Tregs in boosted animals plus/minus MS-275. ***P < 0.0001. Ad, adenoviral; hDCT, human dopachrome tautomerase; VSV, vesicular stomatitis virus.